Sint Martens Latem

Researchers are evaluating two surgical techniques for placing a total knee replacement in patients recently diagnosed with advanced osteoarthritis of the knee. This condition involves cartilage wear that causes pain, stiffness, swelling, and reduced mobility. The study aims to optimize and personalize patient care by comparing the accuracy of robot-assisted and augmented reality-assisted methods for positioning knee prostheses, investigating if both achieve equivalent and comparable results. The trial compares the Skywalker Robotics Assisted Total Knee Arthroplasty (TKA) using the Evolution Medial Pivot Knee with the Pixee Knee+ Augmented Reality assisted TKA using the same knee prosthesis. Both techniques use additional operational data such as angles and axes to optimize implant placement. Participants undergo one of these two surgical methods to assess which technique better facilitates correct instrument placement for the prosthesis. Participants will have their implant positioning assessed through full-leg standing X-rays at one year after surgery to measure radiographic alignment. The study includes patients aged 18 to 85 planned for primary total knee arthroplasty due to osteoarthritis. The researchers will monitor outcomes related to the implant's placement and overall recovery, aiming to understand if these advanced technologies lead to similar surgical precision and patient results.

This research aims to evaluate the safety and effectiveness of Eloralintide (LY3841136) in adults who have osteoarthritis knee pain and are either obese or overweight. Conducted under a master protocol supporting two independent studies, the trial focuses on participants with a body mass index of 27 or higher who experience knee osteoarthritis symptoms such as pain and stiffness. The study is a Phase 3 randomized, double-blind, placebo-controlled trial designed to provide clear evidence on this treatment's impact. Participants will receive either Eloralintide or a placebo, both administered by subcutaneous injection once weekly. The study includes a screening phase followed by about 75 weeks of participation. The treatments aim to assess changes in body weight and knee pain severity. The study excludes participants with recent surgeries for obesity, diabetes, active knee infections, recent serious heart events, or recent use of weight loss medications. During the study, participants will be regularly monitored for changes in body weight and knee pain using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale. Researchers will track safety and effectiveness through scheduled visits and assessments over the approximately 75-week period. The trial will help determine if Eloralintide provides benefits in managing osteoarthritis knee pain alongside obesity or overweight conditions.